REFERENCES
- Wagstaff A J, Bryson H M. Clozapine?. CNS Drugs 1995; 4: 370–400
- Castle D J, Alderton D. Psychopharmacological management of schizophrenia. Pharmacological and Psychosocial Treatments in Schizophrenia, D J Castle, D L Copolov, T Wykes. Martin Dunitz, London 2003; 1–22
- Fitzsimons J, Berk M, Lambert T, Bourin M, Dodd S. A review of clozapine safety. Expert Opinion on Drug Safety 2005; 4: 731–744
- Heiskanen T, Niskanen L, Lyytikainen R, Saarinen P I, Hintikka J. Metabolic syndrome in patients with schizophrenia. Journal of Clinical Psychiatry 2003; 64: 575–579
- Coodin S. Body mass index in persons with schizophrenia. Canadian Journal of Psychiatry 2001; 46: 549–555
- Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychological Medicine 1999; 29: 697–701
- Allison D B, Mentore J L, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 1999; 156: 1686–1696
- George T P, Vessichio J C, Termine A. Nicotine and tobacco use in schizophrenia. Medical Illness in Schizophrenia, J M Meyer, H A Nasrallah. American Psychiatric Publishing, Washington, DC 2003; 81–98
- Henderson D C, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five year naturalistisc study. American Journal of Psychiatry 2000; 157: 975–981
- Meyer J M. Effects of atypical antipsychotics on weight gain and serum lipids. Journal of Clinical Psychiatry 2001; 62(suppl. 27)27–34
- Meyer J M. Cardiovascular illness and hyperlidemia in patients with schizophrenia. Medical Illness in Schizophrenia, J M Meyer, H A Nasrallah. American Psychiatric Publishing, Washington, DC 2003; 53–80
- Henderson D C, Ettinger E P. Glucose intolerance and diabetes in schizophrenia. Medical Illness in Schizophrenia, J M Meyer, H A Nasrallah. American Psychiatric Publishing, Washington, DC 2003; 99–114
- Lambert T J, Chapman L H. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Medical Journal of Australia 2004; 181: 544–548, (on behalf of the consensus development group)
- Merrill D B, Dec G W, Goff D C. Adverse cardiac effects associated with clozapine. Journal of Clinical Psychopharmacology 2005; 25: 32–41
- Bochner F, Allardice J, Ames D, et al. Therapeutic Guidelines: Psychotropic. Therapeutic Guidelines, Melbourne 2003, Version 5
- Bezchlibnyk-Butler K Z. Clinical Handbook of Psychotropic Drugs, 14th edn., K Z Bezchlibnyk-Butler. Hogrefe and Huber, Toronto 2004
- Rossi S. Australian Medicines Handbook, S Rossi. Australian Medicines Handbook, Adelaide 2005
- Tatro D S. Drug Interaction Facts, D S Tatro. Facts and Comparisons Publishing Group, St Louis 2003
- Lacro J P, Dunn L B, Dolder C R, Leckband S G, Jeste D V. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. Journal of Clinical Psychiatry 2002; 63: 892–909